

# NIH TSC Clinical Trial – PREVENTING EPILEPSY USING VIGABATRIN IN INFANTS WITH TUBEROUS SCLEROSIS COMPLEX (PREVeNT Trial)

**NEEDED:** Newborns to 6 months old infants with TSC with NO history of seizures



IRB-160509001



## **What:**

- The objective of this study is to compare the developmental impact of early versus delayed treatment with vigabatrin.
- The results will help determine if treatment with vigabatrin in TSC infants can prevent or lower the risk of developing infantile spasms or refractory seizures.

## **Who:**

Infants up to 6 months old with TSC and no history of seizures may be eligible to participate.

## **Compensation:**

Compensation may be available to help with study related travel expenses.

## **Details:**

For more information, visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Or contact:

prevent@uabmc.edu

Regina Ryan PREVeNT Program Manager

205-975-2890

Martina Bebin, MD, MPA

**Lead Investigator**

# NIH TSC Clinical Trial Sites

## Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT trial)



1. **University of Alabama at Birmingham (UAB)**
2. **Boston Children's Hospital (BCH)**
3. **Cincinnati Children's Hospital Medical Center (CCHMC)**
4. **Mattel Children's Hospital (UCLA)**
5. **University of Texas at Houston (UTH)**
6. **Minnesota Epilepsy Group**
7. **Stanford University**
8. **Beaumont Hospital**
9. **Washington University in St. Louis**
10. **Children's Hospital Orange County (CHOC)**
11. **Children's Hospital of Philadelphia (CHOP)**
12. **Duke University Medical Center**